Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 1179 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

1,179 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,179 programs

Clinical programs

Page 11 of 25

  1. IXAZOMIB

    Takeda

    Follicular Lymphoma

    phase 2 small molecule completed

    1 trial

  2. Idursulfase IT (1 mg)

    Takeda

    Hunter Syndrome

    phase 2 small molecule completed

    1 trial

  3. Ilaprazole

    Takeda

    Esophagitis

    phase 2 small molecule completed

    1 trial

  4. Immune Globulin Infusion (Human), 10% Solution

    Takeda

    Hematologic Malignancies

    phase 2 mab active

    1 trial

  5. Ixazomib

    Takeda

    Triple-Negative Breast Cancer

    phase 2 small molecule terminated

    1 trial

  6. Ixazomib

    Takeda

    Smoldering Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  7. Ixazomib

    Takeda

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  8. Ixazomib

    Takeda

    Myeloid Hematologic Malignancy

    phase 2 small molecule completed

    1 trial

  9. Ixazomib

    Takeda

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  10. Ixazomib

    Takeda

    Multiple Myeloma

    phase 2 small molecule completed

    15 trials

  11. Ixazomib

    Takeda

    Mantle Cell Lymphoma

    phase 2 small molecule active

    2 trials

  12. Ixazomib

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  13. Ixazomib

    Takeda

    ALL, Childhood

    phase 2 small molecule active

    1 trial

  14. Ixazomib 1 MG

    Takeda

    Human Immunodeficiency Virus (HIV)

    phase 2 small molecule completed

    1 trial

  15. Ixazomib/Pomalidomide/Dexamethasone

    Takeda

    Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  16. KER050-MF-301

    Takeda

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  17. Lansoprazole

    Takeda

    Esophagitis

    phase 2 small molecule completed

    1 trial

  18. Lanthanum carbonate

    Takeda

    Chronic Kidney Disease

    phase 2 small molecule completed

    2 trials

  19. Lapaquistat acetate and fenofibrate

    Takeda

    Hyperlipidemias

    phase 2 small molecule completed

    1 trial

  20. Lenalidomide

    Takeda

    Myeloma, Multiple

    phase 2 small molecule active

    1 trial

  21. Leuprorelin

    Takeda

    Prostatic Neoplasms

    phase 2 small molecule completed

    1 trial

  22. Leuprorelin (GF)

    Takeda

    Uterine Fibroids

    phase 2 small molecule completed

    1 trial

  23. Levothyroxine sodium new formulation

    Takeda

    Hypothyroidism

    phase 2 small molecule completed

    1 trial

  24. Lifitegrast

    Takeda

    Dry Eye

    phase 2 small molecule completed

    1 trial

  25. Lifitegrast

    Takeda

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  26. Lubiprostone

    Takeda

    Irritable Bowel Syndrome

    phase 2 small molecule terminated

    3 trials

  27. MCC-135

    Takeda

    Congestive Heart Failure

    phase 2 small molecule completed

    1 trial

  28. MLN0264

    Takeda

    Pancreatic Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  29. MLN0264

    Takeda

    Adenocarcinoma of the Stomach

    phase 2 small molecule terminated

    1 trial

  30. MLN1202

    Takeda

    Atherosclerotic Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

  31. MLN1202 Placebo

    Takeda

    Diabetic Nephropathy

    phase 2 small molecule terminated

    1 trial

  32. Maribavir

    Takeda

    Cytomegalovirus Infection

    phase 2 small molecule completed

    1 trial

  33. Melphalan

    Takeda

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  34. Methylphenidate + SPD503 (Guanfacine hydrochloride)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  35. Mezagitamab

    Takeda

    Relapsed/Refractory

    phase 2 small molecule completed

    1 trial

  36. Mifamurtide

    Takeda

    Osteosarcoma

    phase 2 small molecule terminated

    1 trial

  37. Multivalent recombinant OspA Lyme Borreliosis Vaccine

    Takeda

    Prophylaxis of Lyme Borreliosis

    phase 2 mab completed

    1 trial

  38. NDI-034858

    Takeda

    Psoriatic Arthritis

    phase 2 small molecule completed

    1 trial

  39. NDI-034858 study drug

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  40. NPS 1776 (800 mg)

    Takeda

    Migraine Headache

    phase 2 small molecule completed

    1 trial

  41. NPSP795

    Takeda

    Autosomal Dominant Hypocalcemia (ADH)

    phase 2 small molecule completed

    1 trial

  42. Namilumab

    Takeda

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  43. Namilumab

    Takeda

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  44. Ninlaro

    Takeda

    Immune Thrombocytopenia

    phase 2 small molecule terminated

    1 trial

  45. Niraparib

    Takeda

    Ovarian Cancer

    phase 2 small molecule completed

    2 trials

  46. Niraparib

    Takeda

    Efficacy

    phase 2 small molecule active

    1 trial

  47. Niraparib-Bevacizumab

    Takeda

    Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

    phase 2 small molecule active

    1 trial

  48. Nivolumab

    Takeda

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.